Industry News
Heavyweight board a coup for start-up Farmacule
Queensland molecular farming start-up Farmacule Bioindustries has scored a mini-coup by appointing ex-Dow Chemical heavyweight Dr Paul Zorner to its board. [ + ]
Thrombogenix to change its name
Kinase and blood-clotting disease research group Thrombogenix is within weeks of a name change intended to reflect a broader focus. [ + ]
We'll float when we're ready, says PSL chief
Sydney-based company Proteome Systems Limited (PSL) has participated in a new round of capital raising as speculation mounts about the timing of the company's public float. [ + ]
'Poor performer' biotechs urge shareholders to take the long view
Two biotech companies, Biota Holdings and Progen Industries, have popped up on the Australian Shareholders Association's 2002 list of 'Poor Performers'. [ + ]
Genomic analysis software gets US launch
A new, Melbourne-developed microarray analysis software program is to be unveiled at a major genomics conference in the United States tomorrow. [ + ]
New biotech network aims for power in numbers
A new biotechnology network is aiming for a "power in numbers approach" to garner industry and government support for groups working in the industry. [ + ]
Peptech stands by directors' remuneration
The Australian Shareholders Association (ASA) has clashed with Sydney biotech company Peptech over the company's remuneration of non-executive board members. [ + ]
Growth for GroPep in Biotech Australia buy
Cell growth factor company GroPep is expecting to record a profit within six months after finalising its purchase of Biotech Australia Group. [ + ]
New WEHI spin-off to produce genetic mutation detector
A cheap tool kit to detect genetic mutations is expected to be the first product for the Walter and Eliza Hall Institute's latest spin-off, Gene-Flow. [ + ]
Xenotransplants: not quite around the corner
Pig hearts, kidneys and livers could be available for transplant into humans within five to seven years, according to the latest reports from the American Association for the Advancement of Science meeting currently underway in Boston. [ + ]
Acyte Biotech capitalises on tiny microbes
Two major multinational pharmaceutical companies and two ASX-listed biotechs are vying for the a new biopharmaceutical platform technology developed by Acyte Biotech, a spin-off company from the University of New South Wales. [ + ]
IBM recruits partners for life sciences push
IBM has rolled out a new set of initiatives directed at business partners in the life sciences. [ + ]
Stoush demonstrates need to discuss data sharing
Fresh from a clash between a marine biologist and a Massachusetts Institute of Technology (MIT) associate about sharing and publishing publicly-available research, a group of scientists is meeting this week at the US National Academy of Sciences to try to reach consensus on the issue. [ + ]
Queensland biotech's reclusive benefactor
Self-made billionaire and secretive philanthropist Charles Feeney appears to have a soft spot for Queensland's biotechnology sector. [ + ]
CSL looks to the US after solid half-year result
Blood products and vaccine manufacturer CSL has announced it more than doubled its interim profit to $57.5 million on the back of its acquisition of Swiss plasma supplier ZLB last year. [ + ]
